retatrutide type 2 diabetes phase 2 results a1c 🩺 in diabetes: TRANSCEND-T2D-1 3 → HbA1c ↓2.0% + weight ↓16.8% at 40 weeks. A triple agonist that tackles both glycemia and obesity simultaneously. 📊💊 Ref: Lilly ADA 2026: TRANSCEND-T2D-1: Retatrutide Demonstrates

International Journal of Molecular Sciences, 19 (7), 1987.

CEO Emma Walmsley upgraded the UK firms guidance for 2031 revenues for the second time in a year, from 38bn to 40bn (about $50bn)

Gastrointestinal and liver physiology

doi:10.1007/s12011-017-0951-0 Soheylikhah SEDIGHEH, Dehestani MR, Mohammadi SM, Afkhami AM, Eghbali SA, Dehghan F (2012) The effect of zinc supplementation on serum adiponectin concentration and insulin resistance in first degree relatives of diabetic patients

For individuals who have undergone cholecystectomy, particularly those who experience post-cholecystectomy syndrome characterised by ongoing digestive symptomsthe addition of GLP-1-related gastrointestinal effects may be more troublesome

Front Oncol (2021) 11:727130